Analyst Research

Report Title Price
Provider: Finlabo SIM Spa
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: Directors Deals Ltd.
$12.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sorin SpA Announces FDA Approval and U.S. Launch OF SMARTVIEW Remote Monitoring Solution for Patients with Implanted Cardiac Defibrillators


Friday, 10 May 2013 12:04pm EDT 

Sorin SpA announced it received FDA approval for and is beginning the U.S. launch of the SMARTVIEW remote monitoring solution for patients with implanted cardiac rhythm management (CRM) devices. Using the secure SMARTVIEW remote monitoring solution, physicians and nurses following patients with a Sorin PARADYM RF device can access valuable cardiac data and alert messages from the device while the patient is at home. Sorin launched the PARADYM RF VR and DR implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT-D) devices in the United States in May 2012. PARADYM RF devices are the only clinically proven ICDs that both reduce RV pacing below one percent1, 2 and offer the lowest recorded inappropriate shock rate3 of any devices available to date. The addition of remote monitoring to the PARADYM RF family of devices provides a combination of advanced diagnostic capabilities, early detection of cardiac disease progression, and patient convenience. Installation of the SMARTVIEW remote monitoring system at the patient`s home is assisted by a dedicated helpdesk provided by Sorin. This technical set-up assistance provides patients with peace of mind and removes the installation workload from healthcare professionals. Once the system is installed, patients use the SMARTVIEW system to transmit data electronically from their implanted cardiac device to their physicians. 

Company Quote

1.892
-0.019 -0.99%
18 Dec 2014